Search results for " costs"
Article
Trends in Downstream Bioprocessing
…l bioprocessing, increasing the number of world-class bioprocessing facilities, and lowering overall costs of bioprocessing. This more strategic view is recognized by both end-users and suppliers and…
Article
Scaling Up Novel Therapies
High operational and capital costs
The cost of current technologies is another challenge, says Chatel. “Many processes rely on the culture of adherent cells for producing a range of biological…
Article
Trends in Single-use Bioreactors
Sherman (Sartorius): The same benefits of single-use will apply to continuous processing that apply to batch processing: low capital costs, faster start-up, and fast process changeover. However, there…
Article
Best Practices in Adopting Single-Use Systems
Before long, bioprocessors recognized the value of flexibility, reduced capital costs, and faster campaign turnaround times attainable through disposable bioprocess equipment. Single-use technologies …
Article
Climate Change in Outsourcing
Global bio/pharma companies continue to look for ways to reduce fixed costs and make their cost structures more flexible. That interest has generated big returns for those clinical CROs that have secu…
Article
Improving Upstream Predictability
The end result will be lower capital investment costs, more efficient and flexible operations, and higher yields in less time and space, says Verlenden. Currently, he says, 50–60% of biopharmaceutical…
Article
Mapping a Route for Cell and Gene Therapy Process Development
Reducing manufacturing costs, as well as development of scalable, automated manufacturing processes under closed systems that can reach the target quantities while maintaining the critical quality att…
Article
Cell-Culture Advances Test Bioreactor Performance Models
“Successful modeling of bioreactors can reduce costs associated with engineering testing and engineering runs, accelerating pathways through preclinical and early clinical phases,” adds Mark T. Smith,…
Article
Moving PAT from Concept to Reality
Sartorius also thinks intensified/continuous processing will boost novel PAT solutions, because as companies establish new manufacturing pipelines with unique requirements, they can justify the costs …
Article
Development and Future of Protein A Chromatography Technology: Q&A with Jonathan Royce, Business Leader Chromatography Resins, Cytiva
This week Process Development Forum talks about Protein A with Jonathan Royce, business leader for Cytiva chromatography resins.
mAb purification platforms are very well established, and …